Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Size (2025-2030)

The Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market was valued at $5.28 billion and is projected to reach a market size of $10.21 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 14.1%. 

Opioids are used to relieve pain, but they can also lead to addiction and serious health issues. More people are dealing with opioid use disorder (OUD), which is making it a bigger problem worldwide. This has led to more support from governments and organizations. Buprenorphine-based treatments are key for helping people manage withdrawal symptoms and lower the chances of relapse. On top of traditional medicine, new options like long-lasting injections and digital health tools—like telemedicine and therapy apps—are making it easier for people to get the help they need and stick with it. Partnerships between drug companies and tech firms are bringing about fresh treatment choices and more personalized care. Also, changes in policies and getting more healthcare providers involved are really important for improving access to Medication-Assisted Treatment (MAT). All these changes are creating a more patient-centered approach to tackling the challenges of opioid addiction.

Key Market Insights:

• In 2024, buprenorphine made up around 59.6% of the global market for treating opioid use disorder (OUD), making it the top choice because it helps ease withdrawal symptoms and cravings while keeping misuse low.
• Injectable forms, especially long-acting ones like Sublocade, took a big slice of the market, accounting for about 59.3% of the total revenue. These injectables improve how well patients stick to their treatment and lower the chances of relapse.
• Most OUD medications were distributed through hospital pharmacies, which held about 47.9% of the market share in 2024. They play a key role in handling complicated OUD cases.
• Even though there are changes in policies to encourage more buprenorphine prescriptions, patients still face challenges like not enough providers, insurance problems, and stigma. For example, while the number of prescribers went up by 27% in 2023, only 2% more patients filled their prescriptions.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Key Drivers:

Technological Advances in Treatment Options Drive Market Growth.

New treatments like extended-release buprenorphine, such as Sublocade and Brixadi, provide longer-lasting relief, which means patients don’t have to take their meds as often. This makes it easier for them to stick to their treatment. Plus, using digital health tools helps doctors keep track of patients and create personalized plans, getting everyone more involved in their care.

Growth of Telemedicine and Digital Help.

Telehealth has changed how we treat opioid use disorders by allowing remote appointments and online counseling. This is especially helpful for folks in rural areas who may not have easy access to treatment. It makes getting help more convenient and less intimidating.

Helpful Policy Changes Driving Market Growth.

New government programs are making it easier for people to get medication-assisted treatment by providing better insurance coverage. Changes in regulations, like dropping the need for prior authorization for buprenorphine prescriptions, make it simpler to access these treatments. This encourages more healthcare providers to offer various options for their patients.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Restraints and Challenges:

Facing Challenges in Buprenorphine Treatment for Opioid Use Disorder.

Even though buprenorphine is effective for treating opioid use disorder (OUD), it’s not being used as much as it should be because of a few main issues. In the past, strict rules needed special approvals to prescribe buprenorphine, which created a shortage of doctors who could prescribe it, especially in rural and underserved areas. While recent changes in policies are trying to make these rules easier, they're still causing problems with access. There’s also a lack of training for healthcare providers; many don’t feel confident using buprenorphine properly because they haven’t learned enough about addiction medicine. On top of that, some pharmacies, especially in low-income or remote places, don’t keep buprenorphine in stock because of fears about regulations or stigma, making it hard for people to get the medication when they need it. Insurance issues can also complicate things, like requiring prior approvals that slow down the start of treatment and can discourage both doctors and patients. All these challenges show that we need a better approach that includes changing the rules, improving medical training, encouraging pharmacies to carry buprenorphine, and simplifying insurance processes to help more people access this treatment.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Opportunities:

Innovation, Access, and Support in Opioid Treatment.

The market for treating opioid use disorder with buprenorphine is opening because of new tech, better healthcare approaches, and helpful policy changes. Telemedicine and digital therapies are making it easier for people, especially in remote areas, to get the help they need through online consultations and therapy. Medications like Sublocade and Brixadi are gaining popularity since they require less frequent doses, making it easier for patients to stick with their treatment. Plus, using digital health tools means doctors can adjust treatments in real time, leading to better results. Recent policy updates, like easing prescription rules and expanding insurance for medication-assisted treatment, are also breaking down old barriers and allowing more healthcare workers to provide care. We're seeing new options like mobile treatment units and integrating care into primary healthcare, which will help even more people access the treatment they need. All these changes are making the treatment process smoother and more focused on what patients need as we tackle the issue of opioid addiction head-on.

BUPRENORPHINE-BASED OPIOID USE DISORDERS (OUD) TREATMENT MARKET REPORT COVERAGE:

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation:

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: By Drug Class

• Buprenorphine
• Methadone
• Naltrexone

Naltrexone is quickly becoming a popular choice for treating opioid use disorder (OUD). It's non-addictive and blocks opioid receptors, which helps prevent relapse. The monthly injectable version, Vivitrol, makes it easier for patients since they don’t have to take it daily. With more awareness and insurance coverage increasing, more people, especially in outpatient settings, are choosing it. Naltrexone is also part of longer-term treatment plans that focus on recovery and keeping people from relapsing.

 On the other hand, buprenorphine still leads in the OUD treatment market, holding a big share of global sales. It works as a partial opioid agonist, easing withdrawal symptoms and cravings while reducing misuse and overdose risks. Options like sublingual tablets, films, and the injectable Sublocade give patients flexibility in treatment. Its safety and effectiveness have made it popular, especially in developed countries. Policy changes that increase prescribing options are also helping more people access buprenorphine treatments, keeping them at the forefront of the market.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: By Route of Administration

• Injectable (Parenteral)
• Oral
• Transdermal and Nasal Spray

The injectable form of buprenorphine, especially long-acting options like Sublocade and Brixadi, is the fastest-growing part of the opioid use disorder treatment market. These injections, given weekly or monthly, help keep medication levels steady without daily doses, making it easier for patients to stick to their treatment. They also lower the chances of misuse, which is why more doctors and patients are choosing them for managing opioid use disorders.

Still, the oral method is the most common way to take buprenorphine. Sublingual tablets and films, like Suboxone, are popular because they’re simple to use, affordable, and proven effective. They offer flexible dosing options and can be picked up at local pharmacies, which makes them accessible to many people. Plus, healthcare providers are very familiar with these oral forms, which helps keep them in widespread use.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

Online pharmacies are growing quickly in the buprenorphine treatment market for opioid use disorder (OUD). More people are using digital health platforms and telemedicine, making it easier to get OUD medication. This is especially helpful for folks in rural areas, who can have their prescriptions delivered to their homes, ensuring they stick to their treatment. Online pharmacies teaming up with telehealth services helps with ongoing medication management, boosting their growth.

Right now, hospital pharmacies hold a large share of the buprenorphine market. They play a key role in providing OUD medications, especially for patients in the hospital or those needing injections. Hospitals can give medications in a safe environment, ensuring patients follow their treatment correctly. Also, more opioid treatment programs in places like the U.S. are driving reliance on hospital pharmacies for OUD care.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: Treatment Approach

• Pharmacotherapy
• Behavioral Therapy
• Supportive Services

TeleMAT, which combines telemedicine with medication-assisted treatment for opioid use disorder, is quickly growing. It uses digital platforms to offer remote access to buprenorphine prescriptions and therapy, reaching people who might not have other options. This method has become popular because it tackles geographical and practical challenges while providing a flexible solution to the opioid crisis. By merging medication with online counseling, TeleMAT boosts patient involvement and keeps them in treatment, making it an increasingly common choice for OUD care.

Buprenorphine, especially with naloxone (as in Suboxone), is the main treatment for opioid use disorders. It's effective in reducing cravings and withdrawal symptoms, and it's widely used in various treatment settings. Its safety and ability to lower overdose risks have made it the go-to medication for OUD treatment.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: Emerging Trends

• Digital Therapeutics and Telemedicine
• Regulatory Changes

The rise of digital tools and telemedicine is the biggest trend in treating opioid use disorder with buprenorphine. The COVID-19 pandemic sped up the move to remote care, making a lasting impact on how treatment is delivered. Research shows that starting buprenorphine treatment through telehealth leads to better retention. For example, in Kentucky, 48% of patients who started via telehealth stayed for 90 days, compared to 44% in regular settings. In Ohio, 32% remained in telehealth treatment, while only 28% stuck with traditional care. These results suggest that digital platforms can boost patient involvement and retention in treatment.

Changes in regulations are also a key trend in buprenorphine treatment. The 2022 MAT Act removed the DATA-2000 waiver for prescribers, making it easier for healthcare providers to prescribe buprenorphine. This law has led to more prescribers being able to offer treatment, increasing access for patients. Policy changes have also allowed for more take-home medication and telehealth initiation, making it easier for patients to get the care they need.

Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The market for buprenorphine-based treatment for opioid use disorder is pretty uneven around the world, and that's mainly due to differences in healthcare systems, government rules, and how common opioid use is in different places. North America leads the pack, making up about 66% of the market, thanks to strong medication-assisted treatment programs and solid policy support in the U.S. Europe comes next with around 20%, with countries like the UK, Germany, and France actively using various treatment options. The Asia-Pacific region holds about 5%, but it's growing fast because of rising opioid use and better healthcare access, especially in China and India. Latin America is at roughly 4%, with more awareness and government efforts to tackle opioid addiction. Lastly, the Middle East and Africa account for about 5%, where treatment programs are starting to emerge but are still held back by healthcare challenges. These differences show that there are unique opportunities and obstacles in the buprenorphine treatment market, pointing out the importance of tailored approaches to take on opioid addiction everywhere.

COVID-19 Impact Analysis on the Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market:

The COVID-19 pandemic changed how we treat opioid use disorder with buprenorphine by making telehealth services more common. Before the pandemic, people had to meet in person to get a prescription for buprenorphine, but new policies allowed doctors to start and manage treatment remotely, even just over the phone. This made it easier for folks in rural areas and those who don’t have easy access to healthcare to get help. Research shows that during the pandemic, telehealth not only helped patients stay on their meds but also reduced the risk of overdose. For instance, data from the Veterans Health Administration revealed most buprenorphine visits switched to telehealth, with many people preferring phone calls over video chats because it was easier. But now, there’s worry that the temporary telehealth rules might end, which could limit access and disrupt ongoing treatment. So, it's important to keep pushing for permanent telehealth policies so we can keep improving access to buprenorphine-based treatment.

Trends/Developments:

In December 2024, India's regulatory authorities pushed back the deadline for Quality Control Orders (QCOs) concerning buprenorphine-based treatments for opioid addiction to June 6, 2025. These orders were first issued on December 6, 2023, and had already been postponed twice, with updates in June and September 2024 to give manufacturers more time to meet the new quality and safety standards.

 In September 2024, more changes were made to the QCOs to clarify the rules and respond to feedback from the industry. These adjustments were aimed at making sure buprenorphine-based products meet strict effectiveness and safety standards.

In July 2024, a major pharmaceutical company announced it would invest $200 million to build a new plant for making buprenorphine treatments in Aurangabad, India. They secured a 120-acre site for this facility, which will boost local production, improve supply chains, and support new ideas for opioid addiction treatment.

In June 2024, an amendment to the QCOs was made to revise the regulations for buprenorphine used in opioid addiction treatment. This change gave manufacturers more time to adapt their production to the new compliance requirements.

Key Players:

1. Indivior PLC
2. Alkermes PLC
3. Orexo AB
4. Titan Pharmaceuticals, Inc.
5. Hikma Pharmaceuticals PLC
6. Teva Pharmaceutical Industries Ltd.
7. BioDelivery Sciences International, Inc.
8. Camurus AB
9. Viatris Inc. (formerly Mylan N.V.)
10. Braeburn Inc.